Immuno-Biological Lab, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5.2 times, Exceeds Full-Year Plan

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Feb 10, 2025 3:30 pm JST Earnings

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Earnings Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced its financial results after the market closed on February 10th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) surged 5.2 times that of the same period last year, reaching 129 million yen. The progress rate toward the full-year plan of 120 million yen is 107.5%, already exceeding the target and also exceeding the same period of the previous year of 20.0%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the January to March period (4Q) is expected to turn into a loss of 9 million yen (compared to a profit of 100 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit/loss turned to a profit of 65 million yen (compared to a loss of 5 million yen in the same period last year). The operating profit/loss margin drastically improved from -1.6% in the same period last year to 23.7%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	554	18	-67	-76	-8.2	ー	Feb 6, 2023	J-GAAP
Apr - Dec, 2023	548	10	25	20	2.2	20.0	Feb 2, 2024	J-GAAP
Apr - Dec, 2024	680	124	129	133	14.3	107.5	Feb 10, 2025	J-GAAP
YoY	+24.1%	+1,140.0%	+416.0%	+565.0%	+548.0%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	451	91	95	160	17.3	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	481	52	56	44	4.7	0	Nov 11, 2024	J-GAAP
YoY	+6.7%	-42.9%	-41.1%	-72.5%	-72.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	794	57	-149	-289	-31.1	0	May 12, 2023	J-GAAP
Mar, 2024	816	104	125	186	20.1	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	925	120	120	115	12.4	0	May 14, 2024	J-GAAP
YoY	+13.4%	+15.4%	-4.0%	-38.2%	-38.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	183	-3	-5	-6	-0.7	-1.6	Feb 2, 2024	J-GAAP
Jan - Mar, 2024	268	94	100	166	17.9	35.1	May 14, 2024	J-GAAP
Apr - Jun, 2024	229	51	56	51	5.5	22.3	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	215	17	8	20	2.2	7.9	Nov 11, 2024	J-GAAP
Oct - Dec, 2024	236	56	65	62	6.7	23.7	Feb 10, 2025	J-GAAP
YoY	+29.0%	－	－	－	－